Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
64 results about "Hif prolyl hydroxylase" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
HIF prolyl-hydroxylase is an enzyme involved in the HIF (Hypoxia-inducible factor) signalling pathways, and is the target for a set of therapeutic drugs called HIF prolyl-hydroxylase inhibitors . Hypoxia-inducible factor (HIF) is an evolutionarily conserved transcription factor that allows the cell to respond...
Prolyl Hydroxylase Inhibitors
The invention described herein relates to certain bicyclic heteroaromatic N-substituted glycine derivatives of formula (I)
which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
Owner:SMITHKLINE BECKMAN CORP
Prolyl Hydroxylase Inhibitors
The invention described herein relates to certain bicyclic heteroaromatic N-substituted glycine derivatives of formula (I)which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
Owner:GLAXO SMITHKLINE LLC
N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors
The invention described herein relates to certain pyrimidinedione N-substituted glycine derivatives of formula (I)which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
Owner:SMITHKLINE BECKMAN CORP
Substituted 4-Hydroxypyrimidine-5-Carboxamides
ActiveUS20090239876A1Increase productionReduce productionBiocideOrganic chemistryProlyl HydroxylasesHif prolyl hydroxylase
The present invention relates to substituted 4-hydroxypyrimidine-5-carboxamides useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.
Owner:MERCK SHARP & DOHME LLC
N-Substituted Glycine Derivatives: Hydroxylase Inhibitors
The invention described herein relates to certain pyridazinedione N-substituted glycine derivatives of formula (I)
which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
Owner:GLAXO SMITHKLINE LLC
Prolyl hydroxylase inhibitors
The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I), (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
Owner:GLAXO SMITHKLINE LLC
Prolyl hydroxylase inhibitors
The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I)which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
Owner:GLAXO SMITHKLINE LLC
Prolyl hydroxylase inhibitors
The invention described herein relates to certain bicyclic heteroaromatic N-substituted glycine derivatives of formula (I)
which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
Owner:SMITHKLINE BECKMAN CORP
Spiroindalones
ActiveUS20100137297A1Increase productionReduce productionBiocideOrganic chemistryHif prolyl hydroxylaseProlyl Hydroxylases
The present invention relates to spiroindalone compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.
Owner:MERCK SHARP & DOHME LLC
Spiroazaindoles
ActiveUS20110152304A1Increased endogenous productionReduced endogenous productionBiocideOrganic chemistryProlyl HydroxylasesHif prolyl hydroxylase
The present invention relates to spiroazaindole compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.
Owner:MERCK SHARP & DOHME LLC
Prolyl Hydroxylase Inhibitors
The invention described herein relates to certain quinoxaline-5-carboxamide derivatives of formula (I)which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
Owner:GLAXO SMITHKLINE LLC
Novel 1,8-naphthyridine compounds
The present invention relates to naphthyridine compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.
Owner:MERCK & CO INC
Novel 1.8-naphthyridine compounds
InactiveUS20100056563A1Increased endogenous productionReduced endogenous productionBiocideOrganic chemistryProlyl HydroxylasesHif prolyl hydroxylase
The present invention relates to naphthyridine compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.
Owner:MERCK SHARP & DOHME CORP
N-substituted glycine derivatives: hydroxylase inhibitors
The invention described herein relates to certain pyridazinedione N-substituted glycine derivatives of formula (I)which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
Owner:GLAXO SMITHKLINE LLC
Tetrahydrofuropyridones
The present invention relates to Tetrahydrofuropyridones compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.
Owner:MERCK SHARP & DOHME LLC
Prolyl Hydroxylase Inhibitors
InactiveUS20110160227A1Increase productionOrganic active ingredientsBiocideDiseaseProlyl Hydroxylases
The invention described herein relates to certain bicyclic heteroaromatic N-substituted glycine derivatives of formula (I)
which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
Owner:SHAW ANTONY +1
Prolyl hydroxylase inhibitors
The invention described herein relates to certain pyrimidinedione N-substituted glycine derivatives of formula (I)
which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
Owner:GLAXO SMITHKLINE LLC
Substituted pyrimidines
The present invention relates to substituted pyrimidines useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.
Owner:BIODURO BAONUO TECH BEIJING CO LTD +1
Prolyl Hydroxylase Inhibitors
InactiveUS20100298324A1Increase productionBiocideOrganic active ingredientsDiseaseHif prolyl hydroxylase
The invention described herein relates to certain 4-oxo-2-thioxo-1,2,3,4-tetrahydro-7-quinazolinecarboxamide derivatives of formula (I)
which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
Owner:GLAXO SMITHKLINE LLC
Substituted pyrimidines
The present invention relates to substituted pyrimidines useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.
Owner:MERCK SHARP & DOHME LLC +2
Prolyl Hydroxylase Inhibitors
The invention described herein relates to certain quinoline-8-carboxamide derivatives of formula (I)which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
Owner:GLAXO SMITHKLINE LLC
Tetrahydro-1H-pyrrolo fused pyridones
ActiveUS8372863B2Increase productionReduce productionBiocideOrganic chemistryHif prolyl hydroxylasePyrrole
The present invention relates to tetrahydro-1H-pyrrolo fused pyridone compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.
Owner:MERCK SHARP & DOHME LLC
Prolyl hydroxylase inhibitors
The invention described herein relates to certain quinoline-8-carboxamide derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
Owner:GLAXO SMITHKLINE LLC
Prolyl hydroxylase inhibitors
The invention described herein relates to certain benzimidazol-4-ylcarboxamide derivatives of formula (I)
which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
Owner:GLAXO SMITH KLINE A CORP
Spiroazaindoles
The present invention relates to spiroazaindole compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.
Owner:MERCK SHARP & DOHME LLC
Tetrahydrofuropyridones
The present invention relates to Tetrahydrofuropyridones compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.
Owner:MERCK SHARP & DOHME LLC
Prolyl hydroxylase inhibitors
The invention described herein relates to certain quinoxaline-5-carboxamide derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
Owner:GLAXO SMITHKLINE LLC
Tetrahydrothieno pyridines
ActiveUS20110009425A1Increased endogenous productionReduced endogenous productionBiocideNervous disorderPyridineHif prolyl hydroxylase
The present invention relates to tetrahydrothienopyridine compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.
Owner:MERCK SHARP & DOHME LLC
Application of FG4592 in preparation of medicine for preventing and treating chronic kidney disease caused by ischemia-reperfusion injury
The invention provides application of FG4592 in preparation of a medicine for preventing and treating chronic kidney diseases caused by ischemia-reperfusion injury. The application is characterized in that a new candidate compound is provided for the chronic kidney diseases caused by the ischemia-reperfusion injury; the FG4592 is an HIF prolyl hydroxylase activity inhibitor. In addition, the FG4592 can be prepared into a composition of the medicine for the chronic kidney diseases. Specifically, the FG4592 can promote neogenesis of kidney blood vessels, relieve the kidney oxidative stress caused by the ischemia-reperfusion injury and reduce the kidney fibrosis level. The application range of the FG4592 is expanded; the FG4592 is used as the candidate compound for preventing and treating the chronic kidney diseases caused by the ischemia-reperfusion injury to be developed and applied.
Owner:NANJING CHILDRENS HOSPITAL
Substituted pyrimidines as inhibitors of hif prolyl hydroxylase
The present invention concerns compounds of Formula I that inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.
Owner:MERCK SHARP & DOHME CORP
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Try Eureka
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap